Friday, October 06, 2017 10:49:35 AM
I read the documents correspondence back and forth and the "Final Rejection" response from PTO on 9-28-16 explains why it was rejected for a couple of reasons.
The specific products Dr. Blair, et al are claiming in steps 1 - 4 have already been "claimed" by prior applicants and their technology; Jakobsson in 2002 and Zeikus, et al (Patent # 4,403,032)from similar processes, albeit with enzymes. The focus is on identifying what the specific end reaction product(s) is and percentages. Since someone beat them to it, they can not make a specific product claim for their reaction product, therefore not allowing them to strengthen their patent around the CTS technology. Additionally, the patent reviewer also goes on to cite "non-statutory double-patenting" as the general claims in the new application mirror what was already stated in the issued original patent, 8062428.26 b2, and further supports rejection of this application. From a litigation or enforcement standpoint, this seems huge as anyone can design and operate a similar process, just slightly different, but achieve the same end product. Sounds like anyone could duplicate their CTS process and just add a drop of water to the reactor and the ALLM patent would be useless, since it is based on a "non-aqueous" reaction of solid acid catalyst and material.
So if all they are left with is general claims of making sugars as an end product from CTS process, it doesn't seem like the patent is all that strong or enforceable from a licensing standpoint. This would explain why no license agreements or bolt-ons or plants built in 4 years.
The further you dig, the more clearer things become...Thanks
Recent BIOF News
- Form 8-K - Current report • Edgar (US Regulatory) • 01/24/2024 02:34:54 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/13/2023 05:41:18 PM
- Form D/A - Notice of Exempt Offering of Securities: [Amend] • Edgar (US Regulatory) • 08/17/2023 01:26:03 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/07/2023 05:43:21 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM